US · ICLR
ICON Public Limited Company
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Dublin 18
- Website
- iconplc.com
Price · as of 2024-12-31
$112.85
Market cap 8.26B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $204.89 | +81.56% |
| Intrinsic Value(DCF) | $74.62 | -33.88% |
| Graham-Dodd Method(GD) | $53.70 | -52.42% |
| Graham Formula(GF) | $96.37 | -14.6% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $21.06 | $56.75 | $25.54 | $15.56 | $13.81 |
| 2011 | $21.64 | $46.06 | $1.98 | $8.99 | $4.89 |
| 2012 | $31.83 | $48.62 | $1.77 | $11.94 | $23.25 |
| 2013 | $46.78 | $59.86 | $82.55 | $17.52 | $45.69 |
| 2014 | $67.26 | $79.33 | $123.50 | $21.94 | $56.60 |
| 2015 | $73.25 | $80.81 | $59.14 | $23.38 | $51.87 |
| 2016 | $80.68 | $99.96 | $3.99 | $29.68 | $64.91 |
| 2017 | $122.19 | $106.19 | $7.76 | $33.54 | $70.14 |
| 2018 | $128.28 | $100.25 | $718.33 | $40.62 | $320.09 |
| 2019 | $159.70 | $119.58 | $799.48 | $48.36 | $109.59 |
| 2020 | $182.28 | $175.17 | $403.71 | $48.30 | $48.05 |
| 2021 | $223.88 | $235.74 | $4,486.20 | $0.00 | $228.16 |
| 2022 | $213.91 | $195.65 | $3,544.89 | $25.18 | $294.63 |
| 2023 | $334.64 | $245.18 | $3,080.88 | $39.95 | $94.88 |
| 2024 | $186.56 | $204.89 | $264.38 | $53.70 | $96.37 |
AI valuation
Our deep-learning model estimates ICON Public Limited Company's (ICLR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $204.89
- Current price
- $112.85
- AI upside
- +81.56%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$74.62
-33.88% upside
Graham-Dodd
$53.70
-52.42% upside
Graham Formula
$96.37
-14.6% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ICLR | ICON Public Limited Compa… | $112.85 | 8.26B | +82% | -34% | -52% | -15% | 19.44 | 1.62 | 1.86 | 11.80 | 67.55 | -4.98 | 29.42% | 13.26% | 9.56% | 8.44% | 7.88% | 4.67% | 0.38 | 4.63 | 1.26 | 1.21 | 1.96 | 2878.00% | 199.00% | 963.00% | 7.27% | 0.46 | 8.81% | 0.00% | 0.00% | 6.47% | 16.81 | 16.50 | 2.23 | 2.24 |
| COO | The Cooper Companies, Inc… | $83.67 | 16.63B | -16% | -60% | -63% | -71% | 44.52 | 2.03 | 4.08 | 18.38 | — | 5.96 | 60.67% | 16.69% | 9.16% | 4.59% | 4.21% | 3.03% | 0.34 | 6.83 | 1.89 | 0.84 | 2.54 | -459.00% | 506.00% | 5054.00% | 2.60% | 0.72 | 4.04% | 0.00% | 0.00% | 1.74% | 28.35 | 44.65 | 4.73 | 3.88 |
| EHC | Encompass Health Corporat… | $107.88 | 10.85B | -27% | -39% | -66% | -6% | 19.15 | 3.38 | 1.83 | 7.87 | 78.34 | 6.82 | 21.72% | 17.74% | 9.54% | 21.47% | 20.72% | 8.33% | 0.08 | 8.55 | 1.08 | 0.83 | 0.14 | 2444.00% | 1046.00% | 2190.00% | 4.04% | 1.41 | 10.83% | 0.65% | 12.50% | 24.52% | 10.50 | 25.17 | 1.86 | 3.05 |
| EXAS | Exact Sciences Corporatio… | $103.38 | 19.73B | -34% | -59% | — | — | -93.78 | 8.12 | 6.01 | 171.91 | — | -21.99 | 69.69% | -3.05% | -6.40% | -8.66% | -2.45% | -3.53% | 1.05 | -3.01 | 2.43 | 1.97 | 12.79 | -8032.00% | 1769.00% | 37860.00% | 1.83% | 0.77 | 8.83% | 0.00% | 0.00% | 3.01% | -212.55 | 59.02 | 6.49 | 2.94 |
| GH | Guardant Health, Inc. | $93.90 | 12.32B | -39% | -48% | — | — | -27.78 | -116.44 | 11.77 | -32.21 | — | -57.11 | 64.46% | -44.43% | -42.39% | 348.42% | -117.88% | -23.79% | -16.94 | -111.96 | 4.84 | 4.42 | -3.49 | -674.00% | 3288.00% | -1523.00% | -2.02% | -0.61 | -63.16% | 0.00% | 0.00% | 0.12% | -27.61 | -51.68 | 12.26 | 1.67 |
| MEDP | Medpace Holdings, Inc. | $451.76 | 12.82B | -29% | +273% | -84% | -6% | 29.25 | 28.75 | 5.22 | 22.70 | 139.42 | -55.74 | 30.06% | 21.14% | 17.83% | 70.23% | 171.74% | 22.13% | 0.55 | — | 0.74 | 0.67 | -0.43 | 2098.00% | 1997.00% | 1915.00% | 5.17% | 0.53 | 263.19% | 0.00% | 0.00% | 6.95% | 24.21 | 18.99 | 5.12 | 6.85 |
| NBIX | Neurocrine Biosciences, I… | $132.25 | 13.27B | +32% | +46% | -57% | +4% | 27.52 | 4.05 | 4.60 | 18.16 | 65.61 | 4.05 | 98.18% | 21.64% | 16.73% | 16.38% | 20.21% | 11.46% | 0.13 | — | 3.39 | 2.92 | -0.45 | 4195.00% | 2145.00% | 3437.00% | 5.68% | 1.05 | 36.02% | 0.00% | 0.00% | 5.22% | 19.56 | 16.17 | 4.23 | 7.39 |
| QGEN | Qiagen N.V. | $49.80 | 10.26B | +6% | -52% | -77% | -45% | 23.90 | 2.69 | 4.86 | 14.93 | 5.47 | 14.69 | 61.79% | 24.90% | 20.33% | 11.57% | 10.79% | 7.09% | 0.44 | 15.65 | 3.90 | 2.93 | 1.14 | 43684.00% | 565.00% | -1049.00% | 4.46% | 1.28 | 10.85% | 0.53% | 12.80% | 1.82% | 20.58 | 23.63 | 5.12 | 3.92 |
| RVTY | Revvity, Inc. | $98.31 | 11.15B | +3% | -60% | -88% | -75% | 44.87 | 1.49 | 3.79 | 20.25 | — | -6.33 | 53.08% | 12.49% | 8.46% | 3.23% | 3.28% | 1.96% | 0.48 | 3.87 | 1.68 | 1.25 | 3.92 | -1369.00% | 367.00% | -617.00% | 4.70% | 0.44 | 5.17% | 0.30% | 13.60% | 7.89% | 37.63 | 26.40 | 4.70 | 1.74 |
| SOLV | Solventum Corporation | $74.20 | 12.87B | +72% | -56% | -45% | +7% | 8.17 | 2.52 | 1.53 | 6.62 | 3.68 | -3.91 | 53.47% | 26.20% | 18.69% | 38.86% | 20.41% | 10.82% | 1.00 | 6.29 | 1.23 | 0.61 | 1.63 | 22174.00% | 86.00% | -10124.00% | -0.08% | 0.12 | -0.10% | 0.00% | 0.00% | 24.32% | 7.73 | -1686.63 | 2.03 | 2.15 |
| UHS | Universal Health Services… | $206.10 | 13.12B | -29% | -58% | -24% | +99% | 8.68 | 1.80 | 0.76 | 6.73 | 23.26 | 3.99 | 11.48% | 11.48% | 8.57% | 21.68% | 12.66% | 10.08% | 0.76 | 12.68 | 1.05 | 0.85 | 1.95 | 3734.00% | 971.00% | -2440.00% | 6.47% | 0.58 | 7.04% | 0.39% | 3.40% | 7.77% | 9.27 | 21.78 | 1.07 | 3.24 |
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
- CEO
- Barry Balfe
- Employees
- 41.25K
- Beta
- 1.29
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($74.62 ÷ $112.85) − 1 = -33.88% (DCF, example).